73 results
6-K
EX-99.1
GLPG
Galapagos NV
15 Jun 23
Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer
5:03pm
business transformation and innovation.
“On behalf of the Board of Directors and management of Galapagos, I extend a warm welcome to Thad. Thad … innovation model and played a key role in accelerating the product pipeline through focused growth strategies, investments in innovation, business development
6-K
EX-99.1
GLPG
Galapagos NV
7 Jan 19
Fibrocor and Galapagos sign partnership in fibrosis
7:48am
."
About Fibrocor
Spun out of St. Michael's Hospital and Sinai Health Sytems in Toronto in early 2017, and seed funded by MaRS Innovation, Fibrocor … longitudinal data to uncover rapid progressors of the disease.
MaRS Innovation is a leading provider of commercialization services, early-stage
6-K
EX-99.1
GLPG
Galapagos NV
27 Jun 18
Servier and Galapagos announce start of global ROCCELLA Phase 2 clinical trial with S201086/GLPG1972 in osteoarthritis patients
6:01am
therapeutic innovation that can prevent or slow down the underlying cartilage loss will thus address a huge unmet patient need for the many people … suffering from osteoarthritis", said Philippe Moingeon Head of Center for Therapeutic Innovation at Servier.
OA is a highly prevalent and disabling
6-K
EX-99.1
GLPG
Galapagos NV
29 Aug 19
Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration
4:44pm
. “The collaboration reflects Gilead’s intent to grow our innovation network through diverse and creative partnerships.”
“This agreement is about … maximizing innovation based on developing new mode of action medicines. With the capital provided by Gilead, we aim to progress innovation to patients
6-K
EX-99.1
GLPG
Galapagos NV
20 Sep 23
Galapagos appoints Simon Sturge to its Board of Directors
6:00am
,” commented Mr. Sturge. “I look forward to contributing to the company’s ambition to accelerate science and innovation in its strategic areas of immunology … and innovation for more years of life and quality of life. We focus on the key therapeutic areas of immunology and oncology, where we have developed deep
6-K
EX-99.7
12ilurhnnr4nfr2
20 Sep 19
Current report (foreign)
4:07pm
6-K
EX-99.1
r4rlrq 7wqbex
13 Jun 23
Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board
7:53am
6-K
EX-99.1
x0wpyq0pqogc
23 Jun 22
Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation cell therapies
11:21am
6-K
EX-99.1
udbwjd
27 Jan 22
Galapagos appoints Paul Stoffels as Chief Executive Officer
12:00am
6-K
EX-99.1
vkti24 vcg
15 Jul 19
Gilead and Galapagos Enter into Transformative Research and Development Collaboration
11:59am
6-K
EX-99.1
2uigkpsq07na6
11 Jun 19
Servier and Galapagos complete enrollment of global ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients
6:05am
6-K
EX-99.1
x0cks
4 Nov 22
Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022
4:57pm
6-K
EX-99.1
wahtni
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm
6-K
EX-99.1
3ds6lfwy9tuow57c c6v
31 Mar 23
Current report (foreign)
6:05am
6-K
EX-99.1
0odf6cf0vn48zymmfn
12 Jun 23
Current report (foreign)
7:32am
6-K
EX-99.2
zeaqr6xdfo
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
EX-99.1
9dt ab1qijb2v9uhew
7 Nov 22
Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results
6:08am
6-K
EX-99.1
xaotqyozq bu
24 Aug 22
Galapagos to present at upcoming investor conferences
4:48pm
6-K
EX-99.4
z5n44euoyjljoe hdr
24 Mar 22
Galapagos publishes 2021 annual report and announces Biographies of proposed new board members
8:13pm
6-K
EX-99.1
ix5zcad
29 Mar 24
Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board
6:14am